Immuneering Corporation filed a Form 8-K on November 9, 2026, disclosing the appointment of Grant C. Bogle, MBA, to its Board of Directors as a Class III Director, effective the same date.

Key Highlights

  • New director appointed: Grant C. Bogle, MBA, was appointed to Immuneering Corporation's Board of Directors on November 9, 2026.
  • Director class: Mr. Bogle was appointed as a Class III Director.
  • Compensation: Mr. Bogle will receive compensation in accordance with the company's existing arrangements for non-employee directors, according to the filing.
  • No committee assignment: The filing states Mr. Bogle has not been appointed to any committee of the Board of Directors at this time.
  • No special arrangement: The filing discloses that "there was no arrangement or understanding pursuant to which Mr. Bogle was elected as a director."
  • Indemnification: Mr. Bogle has entered into the company's standard indemnification agreement for directors and officers.

Immuneering Corporation Expands Board With Bogle Appointment

Immuneering Corporation (NASDAQ:IMRX), a Delaware-incorporated company headquartered in Cambridge, Massachusetts, reported the addition of Grant C. Bogle, MBA, to its Board of Directors through an 8-K filing dated November 9, 2026. The appointment, made by the Board itself, places Mr. Bogle in the Class III Director category. The filing was signed by Michael D. Bookman, Chief Legal Officer and Secretary of the company.

According to the filing, Mr. Bogle's compensation will follow the company's standard arrangements for non-employee directors. The filing specifies that he has not been assigned to any Board committee as of the appointment date. The company also disclosed that no outside arrangement or understanding governed Mr. Bogle's election to the Board, and that he has executed the company's standard indemnification agreement applicable to directors and officers.

Immuneering Corporation identifies itself as an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. Its Class A common stock, par value $0.001 per share, is listed on The Nasdaq Global Market under the trading symbol IMRX.

What Was Disclosed

The filing disclosed the appointment of Grant C. Bogle, MBA, as a Class III Director of Immuneering Corporation effective November 9, 2026, including details on his compensation terms, the absence of a committee assignment, and his execution of the company's standard indemnification agreement.